NO20085009L - Nye anvendelser av escitalopram - Google Patents

Nye anvendelser av escitalopram

Info

Publication number
NO20085009L
NO20085009L NO20085009A NO20085009A NO20085009L NO 20085009 L NO20085009 L NO 20085009L NO 20085009 A NO20085009 A NO 20085009A NO 20085009 A NO20085009 A NO 20085009A NO 20085009 L NO20085009 L NO 20085009L
Authority
NO
Norway
Prior art keywords
escitalopram
new uses
isobenzofurancarbonitrile
dimethylamine
fluorophenyl
Prior art date
Application number
NO20085009A
Other languages
English (en)
Inventor
Hans Torgny Svensson
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of NO20085009L publication Critical patent/NO20085009L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Den foreliggende oppfinnelsen vedrører anvendelse av forbindelsen escitalopram (INN-navn), dvs. (S)-1-[3-(dimetylamin)propyl]-1-(4-fluorfenyl)-1,3-dihydro-5- isobenzofurankarbonitril eller et farmasøytisk akseptabelt salt derav for fremstillingen av et medikament for å bedre kognisjon i en tilstand der de kognitive prosesser er svekket.
NO20085009A 2006-05-02 2008-12-02 Nye anvendelser av escitalopram NO20085009L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200600621 2006-05-02
PCT/DK2007/050050 WO2007124757A2 (en) 2006-05-02 2007-04-30 Use of escitalopram for improving cognition

Publications (1)

Publication Number Publication Date
NO20085009L true NO20085009L (no) 2008-12-16

Family

ID=38134951

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20085009A NO20085009L (no) 2006-05-02 2008-12-02 Nye anvendelser av escitalopram

Country Status (15)

Country Link
EP (1) EP2026793A2 (no)
JP (1) JP2009535367A (no)
KR (1) KR20090009820A (no)
CN (1) CN101426494A (no)
AR (1) AR060732A1 (no)
AU (1) AU2007245983A1 (no)
BR (1) BRPI0710230A2 (no)
CA (1) CA2651002A1 (no)
EA (1) EA200870491A1 (no)
IL (1) IL194628A0 (no)
MX (1) MX2008013911A (no)
NO (1) NO20085009L (no)
TW (1) TW200812993A (no)
WO (1) WO2007124757A2 (no)
ZA (1) ZA200808632B (no)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60327634D1 (de) 2002-08-22 2009-06-25 Dainippon Sumitomo Pharma Co Mittel zur behandlung des integrationsdysfunktionssyndroms
AU2004249621B2 (en) 2003-06-23 2009-08-06 Dainippon Sumitomo Pharma Co., Ltd. Therapeutic agent for senile dementia
JP4847320B2 (ja) 2004-02-20 2011-12-28 大日本住友製薬株式会社 統合失調症の記憶・学習機能障害治療薬のｉｎｖｉｖｏスクリーニング方法
WO2009020897A1 (en) * 2007-08-03 2009-02-12 Forest Laboratories Holdings Limited Pharmaceutical compositions containing dopamine receptor ligands and methods of treatment using dopamine recptor ligands
EP2236138A1 (en) * 2009-03-30 2010-10-06 PharmaNeuroBoost N.V. Low dose pipamperone in treating mood and anxiety disorders
US8258139B2 (en) 2010-11-08 2012-09-04 Dainippon Sumitomo Pharma Co., Ltd. Method of treatment for mental disorders
EP3069718A1 (en) * 2015-03-17 2016-09-21 Universidade do Minho Citalopram or escitalopram for use in the treatment of neurodegenerative diseases
US20180193283A1 (en) 2016-12-20 2018-07-12 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine
US11337932B2 (en) 2016-12-20 2022-05-24 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine and polysiloxane or polyisobutylene
EP3644973B1 (en) 2017-06-26 2021-03-24 LTS LOHMANN Therapie-Systeme AG Transdermal therapeutic system containing asenapine and silicone acrylic hybrid polymer
JP2021529737A (ja) 2018-06-20 2021-11-04 エルテーエス ローマン テラピー−ジステーメ アーゲー アセナピンを含有する経皮治療システム
KR102051624B1 (ko) * 2018-11-30 2019-12-02 아밀로이드솔루션 주식회사 트리플루프로마진 또는 이의 약학적으로 허용가능한 염을 유효성분으로 포함하는 퇴행성 뇌질환 치료용 약학 조성물
CN109464436A (zh) * 2019-01-10 2019-03-15 高智玉 西酞普兰或艾司西酞普兰分别和喹硫平联合在制备治疗精神障碍类疾病的复方制剂中的应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK213290D0 (da) * 1990-09-06 1990-09-06 Lundbeck & Co As H Treatment of cerebrovascular disorders
SE9803157D0 (sv) * 1998-09-16 1998-09-16 Astra Ab A new composition
SE9803158D0 (sv) * 1998-09-16 1998-09-16 Astra Ab A new composition
US6617361B2 (en) * 1999-11-05 2003-09-09 Be Able, Llc Behavior chemotherapy
JP2004525867A (ja) * 2000-12-01 2004-08-26 ビー エイブル エルエルシー 行動化学療法
WO2002076461A1 (en) * 2001-03-26 2002-10-03 Serdar Murat Dursun Combination of reboxetine and citalopram
KR20100012089A (ko) * 2001-05-01 2010-02-05 하. 룬트벡 아크티에 셀스카브 경상이성체성 순수 에스시탈로프람의 용도
US20050014848A1 (en) * 2002-01-23 2005-01-20 Pfizer Inc. Combination of serotonin reuptake inhibitors and norephinephrine reuptake inhibitors
WO2004010932A2 (en) * 2002-07-30 2004-02-05 Peter Migaly Combination therapy for depression, prevention of suicide, and varous medical and psychiatric conditions
RS51092B (sr) * 2002-12-23 2010-10-31 H. Lundbeck A/S. Escitalopram bromhidrat i postupak za njegovo pripremanje
AU2004269858A1 (en) * 2003-09-04 2005-03-17 H. Lundbeck A/S The combination of a serotonin reuptake inhibitor and Loxapine
CN101374507A (zh) * 2005-10-14 2009-02-25 H.隆德贝克有限公司 含有依他普仑和安非他酮的稳定药物制剂
EA200801081A1 (ru) * 2005-10-14 2008-10-30 Х. Лундбекк А/С Способы лечения расстройств центральной нервной системы комбинацией малых доз эсциталопрама и бупропиона
US20070134322A1 (en) * 2005-12-14 2007-06-14 Forest Laboratories, Inc. Modified and pulsatile release pharmaceutical formulations of escitalopram

Also Published As

Publication number Publication date
EA200870491A1 (ru) 2009-04-28
BRPI0710230A2 (pt) 2011-08-02
TW200812993A (en) 2008-03-16
AR060732A1 (es) 2008-07-10
WO2007124757A3 (en) 2008-07-24
KR20090009820A (ko) 2009-01-23
JP2009535367A (ja) 2009-10-01
IL194628A0 (en) 2009-08-03
EP2026793A2 (en) 2009-02-25
CN101426494A (zh) 2009-05-06
MX2008013911A (es) 2008-11-12
ZA200808632B (en) 2009-12-30
AU2007245983A1 (en) 2007-11-08
WO2007124757A2 (en) 2007-11-08
CA2651002A1 (en) 2007-11-08

Similar Documents

Publication Publication Date Title
NO20085009L (no) Nye anvendelser av escitalopram
ES2195554T3 (es) Metodo para la preparacion de citalopram.
MA31858B1 (fr) N-phenyl-bipyrrolidine-carboxamides substitues et utilisation therapeutique de ceux-ci
TW200718692A (en) Dihydrobenzofuran derivatives and uses thereof
MA32797B1 (fr) Formes cristallines de la (r)-5[3-chloro-4-(2,3-dihydroxy-propoxy)-benz-[z]-ylidène]-2-([z]-propylimino)-3-o-tolyl- thiazolidin-4-one
BRPI0818626A2 (pt) n-fenil-bipirrolidina carboxamidas substituída e uso terapêutico da mesma
WO2009013212A3 (en) Dual modulators of 5-ht2a and d3 receptors
ATE491446T1 (de) Ligustilid zur behandlung von erkrankungen des zentralen nervensystems
ATE467632T1 (de) Pyrroloä2,3-büpyridinderivate als modulatoren des h3-rezeptors
ATE449776T1 (de) Pyrroloä2,3-cüpyridinderivate
EA200601194A1 (ru) Новые производные бензофурана, используемые для профилактики или лечения нарушений, связанных с 5-ht-рецептором
ATE412636T1 (de) Piperazinylpyridinderivate als mittel gegen adipositas
TR200708792T1 (tr) Kristal esitalopram bazı ve esitalopram içeren ağızda dağılan tabletler
PE20040924A1 (es) Bromhidrato de escitalopram y un metodo para su preparacion
DK1893589T3 (da) Substituerede N-benzo[d]isoxazol-3-yl-amin-derivater som inhibitorer af mGluR5-, serotonin-(5-HT) og noradrenalinreceptorer og deres anvendelse til fremstilling af lægemidler
MX2010001195A (es) Derivados de benzoil-peperidina como moduladores dobles de los receptores 5-ht2a y d3.
WO2008059514A3 (en) Process for preparing escitalopram
WO2008126106A3 (en) Novel and improved processes for the preparation of intermediates of darifenacin, darifenacin and its pharmaceutically acceptable salts
WO2005112640A3 (en) Compounds, compositions and methods for treatment and prophylaxis of hepatitis c viral infections and associated diseases
ATE434446T1 (de) Wirksubstanzkombination mit einer verbindung mit npy rezeptor-affinität und einer verbindung mit 5-ht6 rezeptor-affinität
TH91931B (th) การใช้แบบใหม่ของเอสซิแทลอแพรม
TH91931A (th) การใช้แบบใหม่ของเอสซิแทลอแพรม
NO20051639D0 (no) EMSELEX-Darifenacin. Kjemisk navn: 3-(S)-(-)-(1-karbamoyl-1,1-difenylmetyl)-1-[2-(2,3-dihydrobenzofuran-5-yl)etyl]pyrrolidin
NO20073390L (no) Fenylpiperaziner med en kombinasjon av affinitet for dopamin-D2-reseptorer og serotoningjenopptaksseter
NO20073387L (no) Benzdioksanpiperazinderivater med en kombinasjon av affinitet for dopamin-D2-reseptorer og serotoninreopptaksseter

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application